Genotyping analysis as a possible predictor of pharmacokinetic and clinical effects of antipsychotic drugs
Authors:
- 31 July 2002
- journal article
- Published by Elsevier in International Congress Series
- Vol. 1244, 111-118
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4Naunyn-Schmiedeberg's Archives of Pharmacology, 1999
- Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidolProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1998
- Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquineEuropean Journal of Clinical Pharmacology, 1996
- Pharmacogenetic Phenotyping and GenotypingClinical Pharmacokinetics, 1994
- Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjectsClinical Pharmacology & Therapeutics, 1993
- Haloperidol Disposition Is Dependent on the Debrisoquine Hydroxylation PhenotypeTherapeutic Drug Monitoring, 1992
- Haloperidol plasma levels and clinical response: a therapeutic window relationshipAmerican Journal of Psychiatry, 1992
- Haloperidol Disposition Is Dependent on Debrisoquine Hydroxylation PhenotypeTherapeutic Drug Monitoring, 1992
- Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotypeClinical Pharmacology & Therapeutics, 1991
- Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beingsClinical Pharmacology & Therapeutics, 1989